Abstract
We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 1241-1245 |
| Number of pages | 5 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 29 |
| Issue number | 7 |
| Publication status | Published - 2002 Jul |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Cite this
A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer. / Saikawa, Yoshiro; Kanai, Toshio; Kawano, Yukio; Otani, Yoshihide; Kubota, Tetsuro; Kitajima, Masaki.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 29, No. 7, 07.2002, p. 1241-1245.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer
AU - Saikawa, Yoshiro
AU - Kanai, Toshio
AU - Kawano, Yukio
AU - Otani, Yoshihide
AU - Kubota, Tetsuro
AU - Kitajima, Masaki
PY - 2002/7
Y1 - 2002/7
N2 - We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.
AB - We used a novel combination chemotherapy of TS-1 and low-dose cisplatin (CDDP) with 4 gastric cancer patients with liver metastases (one far advanced and 3 recurrent patients). TS-1 was administered at 80 mg-120 mg/body/day, twice daily for 3 weeks followed by a 2-week interval as one cycle, and CDDP was administered at 6 mg/m2/day div, for 5 days followed by a 2-day interval (1 cycle for an inpatient) or at 6 mg/m2/day div, at 5 times for 2-3 weeks (1 cycle for an outpatient). Efficacy and toxicity were evaluated after 3-6 cycles of the regimen, as long as the patients tolerated the regimen without severe side effects. This regimen resulted in 1 complete response, 2 partial responses and 1 progressive disease, showing a 75% efficacy rate. One patient experienced grade 2 nausea from this regimen, which was ameliorated by means of prolonging the interval of CDDP-administration. Thus, the regimen is useful to maintain patients' quality of life without severe adverse effects, and has a high efficacy in gastric cancer patients with liver metastases.
UR - http://www.scopus.com/inward/record.url?scp=0036635632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036635632&partnerID=8YFLogxK
M3 - Article
VL - 29
SP - 1241
EP - 1245
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 7
ER -